Mega Lifesciences (MEGA) Q2 2026 earnings summary

Executive summary

• Operating revenue for 1H26 reached THB 6,942 mn, up 12.5% year-over-year, with both Mega We Care and Maxxcare segments delivering double-digit growth.

• Gross margin improved to 52.0% in 1H26 from 50.5% in 1H25, driven by better segmental margins.

• EBITDA rose 33.8% year-over-year to THB 1,613 mn in 1H26, and reported net profit increased 33.1% to THB 1,119 mn.

• Adjusted net profit for 1H26 was THB 1,028 mn, up 11.7% year-over-year, reflecting strong core business performance.

• Interim dividends of THB 0.85 per share were approved, representing 66.2% of 1H26 net profits.

Financial highlights

• 2Q26 operating revenue was THB 3,534 mn, up 10.7% year-over-year.

• Gross profit for 2Q26 was 51.7% of revenue, up from 49.7% in 2Q25.

• SG&A expenses for 1H26 were THB 2,288 mn, up 11.1% year-over-year, stable at 33.0% of revenue.

• Operating cash flow for 1H26 was THB 848 mn, representing 76% of reported net profit, with lower cash conversion due to increased inventory.

• Cash and bank balances as of 30 Jun 2026 were THB 4,008 mn.

Outlook and guidance

• Focus remains on strengthening leadership in Southeast Asia and expanding in Sub-Saharan Africa through new products, partnerships, and acquisitions.

• Planned capex of THB 2.6 bn over 2026-2028 for new manufacturing facilities in Vietnam, Myanmar, and Indonesia.